Education
About Us
Working with TipRanks
Follow Us
Taiko Pharmaceutical Co., Ltd. (JP:4574)
:4574
4574 Stock Chart & Stats
¥305.00
-¥2.00(-0.62%)
At close: 4:00 PM EST
¥305.00
-¥2.00(-0.62%)
Day’s Range― - ―
52-Week Range¥228.00 - ¥444.00
Previous CloseN/A
Volume146.60K
Average Volume (3M)93.84K
Market Cap
¥14.82B
Enterprise Value¥11.43B
Total Cash (Recent Filing)¥4.14B
Total Debt (Recent Filing)¥1.32B
Price to Earnings (P/E)16.2
Beta0.83
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.05
Shares Outstanding50,636,900
10 Day Avg. Volume93,940
30 Day Avg. Volume93,840
Financial Highlights & Ratios
PEG Ratio6.05
Price to Book (P/B)1.76
Price to Sales (P/S)2.34
P/FCF Ratio28.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.92
Revenue Forecast (FY)¥6.08B
Bulls Say, Bears Say
Bulls Say
Improved LeverageMaterial debt reduction to ~¥0.82B with sizable equity (~¥8.52B) meaningfully improves balance-sheet flexibility. This durable de-risking lowers refinancing and interest burden, increases capacity for R&D investment or partnerships, and strengthens resilience to sector shocks over the medium term.
Return To ProfitabilityA sustained earnings recovery in 2024–2025 with positive operating profit and ~¥0.9B net income indicates the business can generate profits from current operations. Durable profitability supports internal funding for development, reduces reliance on external capital, and enables strategic reinvestment.
Positive Cash Flow RecoveryOperating and free cash flow turned positive and strengthened in 2024–2025, providing an ongoing source of liquidity. Improving cash generation enhances the firm's ability to fund working capital, R&D and manufacturing without heavy external financing, supporting durable operational autonomy.
Bears Say
Earnings VolatilityMulti-year swings—from strong profits in 2020 to heavy losses 2021–2023 and then recovery—highlight inconsistent earnings quality. This structural volatility complicates forecasting, budgeting and investment decisions, and raises execution risk for sustaining margins and cash conversion long term.
Uneven Revenue TrendModest, uneven revenue growth after a post-2020 contraction suggests the top line lacks steady momentum. For a specialty/generic drug maker, inconsistent revenue trends can limit scale economies, constrain predictable R&D funding, and leave the company exposed to product lifecycle and competitive pressures.
Historic Weak Returns And Shrinking AssetsDeeply negative returns on equity in prior years and a declining asset base indicate periods when capital produced poor returns. This legacy weakens structural earning power, may limit reinvestment capacity, and implies management must sustain improvements to restore long-term return profiles.
Taiko Pharmaceutical Co., Ltd. News
4574 FAQ
What was Taiko Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Taiko Pharmaceutical Co., Ltd. lowest stock price was ¥228.00 and its highest was ¥444.00 in the past 12 months.
What is Taiko Pharmaceutical Co., Ltd.’s market cap?
Taiko Pharmaceutical Co., Ltd.’s market cap is ¥14.82B.
When is Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 08, 2026 which is in 62 days.
How were Taiko Pharmaceutical Co., Ltd.’s earnings last quarter?
Taiko Pharmaceutical Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥5.05 earnings per share for the quarter, beating the consensus estimate of N/A by ¥5.05.
Is Taiko Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Taiko Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Taiko Pharmaceutical Co., Ltd. pay dividends?
Taiko Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥13 which represents an annual dividend yield of N/A. See more information on Taiko Pharmaceutical Co., Ltd. dividends here
What is Taiko Pharmaceutical Co., Ltd.’s EPS estimate?
Taiko Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Taiko Pharmaceutical Co., Ltd. have?
Taiko Pharmaceutical Co., Ltd. has 50,636,900 shares outstanding.
What happened to Taiko Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Taiko Pharmaceutical Co., Ltd. reported an EPS of ¥5.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.318%.
Which hedge fund is a major shareholder of Taiko Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4574
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Taiko Pharmaceutical Co., Ltd.
Taiko Pharmaceutical Co.,Ltd. engages in pharmaceuticals, infection control, and other businesses. The company manufactures and sells non-prescription drugs under the Seirogan and Seirogan Toi-A brands for the treatment of loose stools, diarrhea, food and water poisoning, vomiting, and related conditions; tablets for diarrhea; and quasi-drugs, such as Trumpet Intestinal Regulator BF. It also manufactures and sells sanitation control products under the Cleverin brand name to wholesalers, as well as Cleverin generator, a machine that emits low concentrations of chlorine dioxide gas; and supplies products using the patented Cleverin technology through OEM agreements and products developed jointly with other companies. It exports its products to the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was incorporated in 1946 and is headquartered in Osaka, Japan.`
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
Nippon Chemiphar Co., Ltd.
―